Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Aug 2018
At a glance
- Drugs LOAd 703 (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Lokon Pharma
- 12 Nov 2016 Status changed from not yet recruiting to recruiting.
- 20 Sep 2016 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.
- 20 Sep 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Nov 2018.